Cornea/External Disease News

The first Canadian patient has been dosed in a phase 1/2 trial of a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.

Nearly 5 months after the FDA did not approve reproxalap for dry eye, Aldeyra Therapeutics has announced a plan to resubmit a new drug application for the reactive aldehyde species modulator, according to a press release.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Douglas Katsev, MD, and Julia Katsev Larson, OD, discuss the use of Miebo for dry eye disease.

Okyo Pharma has announced additional findings from its phase 2 trial of OK-101, including statistically significant improvement in ocular pain relief, conjunctival staining and tear breakup time in patients with dry eye disease.

Although we all learned about corneal disease in optometry school, both the understanding of keratoconus and expanding protocols for its treatment have changed dramatically since many practicing optometrists graduated.

When children and teens present with early onset of keratoconus, we often see severe disease and rapid progression.

NEW YORK — Reimbursement and pipeline products, as well as educating patients and doctors about Demodex blepharitis, remain priorities for Tarsus Pharmaceuticals in the wake of Xdemvy’s launch, a company executive said at Vision Expo East.

Optometrists are often first to diagnose a patient with keratoconus and hold a great responsibility for referring patients for corneal cross-linking in a timely manner.

FRANKFURT, Germany — The ELZA epi-on corneal cross-linking protocol provides biomechanical stiffening comparable to epi-off CXL, without iontophoresis or additional oxygen, in the office at the slit lamp.

The nonprofit eye bank Eversight has partnered with Emmecell, a clinical-stage biotechnology company, to advance therapies involving donor corneal epithelial cells for treatment of eye disease.